T-cell Lymphoma Market Size is valued at 2140.00 Million in 2024 and is predicted to reach 4733.84 Million by the year 2034 at a 8.4% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
T-cell lymphoma is a rare type of cancerous lymphoma that begins in white blood cells (T cells). Lymphoma arises from the uncontrolled growth of mature T cells and can become cancerous. It can cause skin redness, scaly round patches on the skin, and skin tumors.
Several factors driving the growth of the T-cell Lymphoma Market include the rising lymphoma cancer cases, increasing technological advances in therapy techniques, increasing T-cell lymphoma-specific therapies, and increasing autoimmune disorders. Moreover, spreading awareness regarding the benefits of T-cell lymphoma therapeutics, surging demand for cost-efficient cancer treatments and boosting government funding for the R&D of innovative cancer therapies are further expected to deliver considerable market growth during the forecast period. According to Leukemia & Lymphoma Society 2020, around 85,720 new lymphoma cases were diagnosed in the United States in 2020. Additionally, the newly reported lymphoma cases include 8,480 cases of Hodgkin (HL) and 77,240 cases of Non-Hodgkin (NHL) Lymphoma, thereby upsurging the demand for this market.
However, the high cost of T-cell Lymphoma therapies, complicated production methods, and side effects of these therapies may restrict the market growth in the upcoming years.
The T-cell Lymphoma Market is classified based on lymphoma type, therapy, and region. By lymphoma type, the market is segmented into peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. Peripheral T-cell lymphoma is further divided into cutaneous T-cell lymphoma, anaplastic large cell lymphoma, angio-immuno-blastic T-cell lymphoma, and others (intestinal T-cell lymphoma, follicular T-cell lymphoma). By therapy, the market is grouped into radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others (antiviral treatment, etc.). The chemotherapy segment is expected to lead this market during the forecast years due to its increasing use for cancer treatments. Regionally, the market is segregated across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is anticipated to dominate the T-cell lymphoma market over the forecast period (2020-2030), owing to the increasing R&D expenditure and rising incidences of lymphoma in this region.
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 2140.00 Million |
|
Revenue forecast in 2031 |
USD 4733.84 Million |
|
Growth rate CAGR |
CAGR of 8.4% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Therapy, Lymphoma Type |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Elorac, F. Hoffmann-La Roche Ltd, Genmab A/S, Genor Biopharma, GlaxoSmithKline plc., Innate Pharma, Johnson and Johnson Private Limited, Kyowa Kirin Co., Ltd., Merck and Co. Inc., Novartis AG, Pfizer, Roche, Seagen Inc., Secura Bio, Shanghai Junshi Bio, SHIONOGI & Co., Ltd., Solasia, Spectrum Pharmaceuticals Inc., Takeda, Viracta, and Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global T-cell Lymphoma Market Snapshot
Chapter 4. Global T-cell Lymphoma Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global T-cell Lymphoma Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on T-cell Lymphoma Market Industry Trends
Chapter 5. T-cell Lymphoma Market Segmentation 1: By Therapy, Estimates & Trend Analysis
5.1. Market Share by Therapy, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Therapy:
5.2.1. Radiotherapy
5.2.2. Chemotherapy
5.2.3. Immunotherapy
5.2.4. Stem Cell Transplantation
5.2.5. Others (Antiviral Therapy, etc.)
Chapter 6. T-cell Lymphoma Market Segmentation 2: By Lymphoma Type, Estimates & Trend Analysis
6.1. Market Share by Lymphoma Type, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Lymphoma Type:
6.2.1. Peripheral T-cell Lymphoma
6.2.1.1. Cutaneous T-cell Lymphoma
6.2.1.2. Anaplastic Large Cell Lymphoma
6.2.1.3. Angio-immuno-blastic T-cell Lymphoma
6.2.1.4. Others
6.2.1.4.1. Intestinal T-cell Lymphoma
6.2.1.4.2. Follicular T-cell lymphoma
6.2.2. T-cell Lymphoblastic Lymphoma
Chapter 7. T-cell Lymphoma Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global T-cell Lymphoma Market , Regional Snapshot 2023 & 2031
7.2. North America
7.2.1. North America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031
7.2.3. North America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031
7.3. Europe
7.3.1. Europe T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031
7.3.3. Europe T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031
7.4. Asia Pacific
7.4.1. Asia Pacific T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031
7.4.3. Asia Pacific T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts By Lymphoma Type, 2024-2031
7.5. Latin America
7.5.1. Latin America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031
7.5.3. Latin America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031
7.6. Middle East & Africa
7.6.1. Middle East & Africa T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031
7.6.3. Middle East & Africa T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. 4SC AG
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Overview
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Acrotech Biopharma
8.2.3. Affimed
8.2.4. Bausch Health Companies Inc.
8.2.5. Biocryst Pharmaceuticals Inc.
8.2.6. Bristol-Myers Squibb Company
8.2.7. Chipscreen Biosciences
8.2.8. Citius Pharma
8.2.9. CSPC
8.2.10. CStone Pharmaceuticals
8.2.11. Daiichi-Sankyo
8.2.12. Dizal Pharma
8.2.13. Eisai
8.2.14. Elorac
8.2.15. Hoffmann-La Roche Ltd
8.2.16. Genmab A/S
8.2.17. Genor Biopharma
8.2.18. GlaxoSmithKline plc.
8.2.19. Innate Pharma
8.2.20. Johnson and Johnson Private Limited
8.2.21. Kyowa Kirin Co., Ltd.
8.2.22. Merck and Co. Inc.
8.2.23. Novartis AG
8.2.24. Pfizer
8.2.25. Roche
8.2.26. Seagen Inc.
8.2.27. Secura Bio
8.2.28. Shanghai Junshi Bio
8.2.29. SHIONOGI & Co., Ltd.
8.2.30. Solasia
8.2.31. Spectrum Pharmaceuticals Inc.
8.2.32. Takeda
8.2.33. Viracta
8.2.34. Other Prominent Players
Global T-cell Lymphoma Market, by Lymphoma Type, 2020-2030 (Valu US$ Mn)
Global T-cell Lymphoma Market, by Therapy, 2020-2030 (Value US$ Mn)
Global T-cell Lymphoma Market, by Region, 2020-2030 (Value US$ Mn)
North America T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)
Europe T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)
Asia Pacific T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)
Latin America T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)
Middle East & Africa T-cell Lymphoma Market, by Country, 2020-2030 (Value US$ Mn)
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
